<DOC>
	<DOCNO>NCT00273494</DOCNO>
	<brief_summary>Hypothesis surgery benefit locally advance NSCLC N2 disease . Patients randomise surgery .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Plus/Minus Surgery Non-Small-Cell Lung Cancer ( NSCLC ) Stage IIIA/N2</brief_title>
	<detailed_description>Patients stag randomised neoadj . chemotherapy follow surgery follow irradiation chemotherapy follow irradiation . Endpoint survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically verify NSCLC Stage IIIA/N2 age 1875 Lung function test allow surgery Mediastinoscopy perform Prior chemotherapy Prior irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>N2 disease</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Surgery</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
</DOC>